Established services anchor demand; monitoring expands faster
Screening, health examinations and preventive services account for approximately two-thirds of market revenue in 2025 and are expected to generate around 60% of incremental revenue through 2032. Continuous monitoring gains share as sustained use and consumable replenishment support recurring demand.
The commercial opportunity extends beyond adoption of new tests or algorithms. Repeat screening, completed diagnostic pathways, paid clinical cases and sustained participation determine how demand becomes revenue. The report examines these differences across laboratory testing, imaging AI, coronary analytics, vaccines and digital prevention.
Regional opportunity depends on payment and delivery
North America is projected to remain the largest revenue market. Europe and Asia Pacific are expected to be similar in size by 2032, each representing approximately 29% of global revenue. Organized screening and public procurement shape European demand, while broader examination coverage and monitoring adoption support Asia Pacific growth.
Regional analysis covers insurance reimbursement, self-pay, employer contracts and public programs, highlighting how purchasing arrangements influence market entry and recurring service delivery.
What the report covers
-
Market size and structure: Global estimates for 2025 and forecasts for 2032, with business-level revenue breakdowns for screening and preventive services, vaccine products, and continuous monitoring devices and directly associated services.
-
Regional outlook: North America, Europe, Asia Pacific and other regions, including market values, shares and 2025–2032 growth rates.
-
Early detection: Molecular colorectal screening, multicancer early detection and screening imaging AI.
-
Risk identification: Coronary analytics, clinical risk workflows, continuous monitoring and digital biomarkers.
-
Preventive interventions: Employer and health-plan programs, public prevention services, engagement, retention and delivery economics.
-
Competitive landscape: Testing platforms, imaging AI businesses, laboratory networks, examination providers and digital health companies.
-
Payment models: Testing fees, paid-case analytics, software subscriptions, member service fees, public procurement and performance-linked payments.
Participants examined
Coverage includes Abbott/Exact Sciences, Guardant Health, GRAIL, Geneoscopy/Labcorp, Heartflow, Cleerly, Lunit, RadNet/DeepHealth, Dexcom/Oura, Omada Health, Virta Health, Quest Diagnostics, Meinian Onehealth, Terveystalo/Feelgood and Sonde Health. Vaccine coverage includes GSK, Merck/MSD, Pfizer and Sanofi.
Report contents
- Market Development and Value Creation
- Early Detection: Established Screening and Multicancer Testing
- Risk Identification and Clinical Workflows
- Preventive Interventions and Service Revenue
- Key Participant Strategies and Competitive Landscape
- Regional Market Size and Payment Models
- Commercial Pathways and Growth Conditions
Delivery details
Format: English PDF
Length: 19 pages
Publication: October 2026
Market sizing: 2025 estimates and 2032 forecasts
Included: Six tables and 47 references
The report supports market opportunity assessment, partnership evaluation and commercial planning by connecting category growth with the practical conditions for adoption, payment and continuing use.
